Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Tricuspid Valve Regurgitation in Heart Failure - A Pathophysiology-based Holistic Approach for Individualized Patient Management.

European journal of heart failure·2026
Same author

AI as a peer reviewer: a blinded comparative study of LLM-generated and human reviews in a cardiology journal.

European heart journal. Imaging methods and practice·2026
Same author

Outcomes after tricuspid transcatheter edge-to-edge repair: a systematic review and meta-analysis.

Annals of cardiothoracic surgery·2026
Same author

Right Ventricular Function and Echocardiographic Characteristics After Left Atrial to Coronary Sinus Shunting; Insights from ALT-FLOW Early Feasibility Study 3 Year Follow-Up.

Journal of cardiac failure·2026
Same author

Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR.

ESC heart failure·2026
Same author

Impact of Previous Cardiac Surgery on Outcomes After Tricuspid Valve Transcatheter Edge-to-Edge Repair: Insights from EuroTR.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Related Experiment Video

Updated: Jun 2, 2025

Non-invasive Assessment of Microvascular and Endothelial Function
05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

16.2K

Focusing on microvascular function in heart failure with preserved ejection fraction.

Ornela Velollari1,2, Karl-Philipp Rommel1,2, Karl-Patrik Kresoja1,2

  • 1Department of Cardiology, Cardiology I, University Medical Center Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.

Heart Failure Reviews
|January 13, 2025
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) is rising globally. Coronary microvascular dysfunction (CMD) significantly impacts HFpEF, necessitating targeted therapies for improved patient outcomes.

Keywords:
Coronary microvascular dysfunctionCoronary sinus reducerHeart failureIschemiaTherapy

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Related Experiment Videos

Last Updated: Jun 2, 2025

Non-invasive Assessment of Microvascular and Endothelial Function
05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

16.2K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Translational Medicine

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a growing global health concern, accounting for half of all heart failure cases.
  • The pathophysiological heterogeneity and limited understanding of HFpEF mechanisms hinder effective treatment development.
  • Coronary microvascular dysfunction (CMD) is increasingly implicated in HFpEF, though its precise causal role remains unclear.

Purpose of the Study:

  • This review examines the prevalence, prognostic significance, and therapeutic targets of CMD in HFpEF.
  • It aims to clarify the complex relationship between CMD and HFpEF.
  • The review seeks to identify potential new therapeutic strategies for HFpEF.

Main Methods:

  • Literature review of existing studies on HFpEF and CMD.
  • Analysis of the proposed pathophysiological links between CMD and HFpEF.
  • Evaluation of current and emerging therapeutic interventions.

Main Results:

  • CMD may contribute to HFpEF through impaired coronary blood flow, myocardial ischemia, and adverse cardiac remodeling.
  • HFpEF-related cardiac stress can exacerbate CMD by increasing coronary resistance.
  • Metabolic abnormalities may underlie both CMD and HFpEF.

Conclusions:

  • Current HFpEF treatments show limited efficacy, underscoring the need for targeted therapies.
  • The coronary sinus reducer is a potential therapeutic device for improving myocardial perfusion in HFpEF.
  • Further research is crucial to elucidate the CMD-HFpEF link and develop phenotype-specific treatments.